AbbVie

PharmaceuticalsNorth Chicago, IllinoisABBVAbout 57,000 employees

More about AbbVie

Drugmaker that develops and sells medicines in immunology, neuroscience and oncology, plus Allergan aesthetics products such as Botox

Revenue

$61.2B

Fiscal 2025, up about 9%

Employees

About 57,000

As of December 2025

Stock

ABBV

New York Stock Exchange

Headquarters

North Chicago, Illinois

CEO

Robert Michael

Since July 2024

BrandsSkyrizi, Rinvoq, Humira, Vraylar, Botox

Current strategyGrowing newer immunology drugs as Humira faces biosimilars and adding to its pipeline, including the proposed Apogee Therapeutics acquisition announced in July 2026

Recent workforce changes85 roles cut in Irvine, California in July 2026 and 59 in the Bay Area in January 2026 (WARN notices)

CompetitorsJohnson & Johnson, Eli Lilly, Bristol Myers Squibb

Checked October 11, 2026 · Sources: sec.gov, sec.gov (2), warntracker.com, warntracker.com (2)

No source-backed updates for AbbVie yet. They appear here when a public report or filing covers the company.

No one has posted about AbbVie yet. Be the first to post ›

Follow AbbVie in a feed reader, no account needed: RSS feed